Blood Coagulation Disorders clinical trials
The registry lists 147 studies for Blood Coagulation Disorders across more than 10 countries. 15 are recruiting or about to start. 60 of them are mainly about Blood Coagulation Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its 15 narrower conditions too, such as Hemophilia A: 2,162 studies, 437 open.
Get an email when these change. Save the Blood Coagulation Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Swedish Orphan Biovitrum (10) · BioMarin Pharmaceutical (8) · Bayer (4) · Seoul National University Bundang Hospital (4) · Spark Therapeutics, Inc. (3) · CSL Behring (3) · University of Chicago (3) · Novartis Pharmaceuticals (2)
What is being tested here
Drugs under test in Blood Coagulation Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8, phase 3 first
- Dec 2026A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) · Phase 3 · Kedrion S.p.A.
- Mar 2027Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa · Phase 3 · Swedish Orphan Biovitrum
- Jun 2027Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery · Phase 3 · CSL Behring
- Dec 2026Early Genomic Testing for Inherited Bleeding Disorders · Queen's University
- Dec 2026Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD) · Scientific Institute San Raffaele
- Mar 2027External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Jun 2027Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent · Centre Hospitalier Universitaire de Saint Etienne
- Nov 2027The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing · University of Chicago
Who these studies take
Of the 12 Blood Coagulation Disorders studies recruiting now, 8 (67%) set no upper age limit and 3 (25%) stop at 75 or younger. 5 (42%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (25%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (25%) | 3 (25%) |
| 18 | 12 (100%) | 12 (100%) |
| 30 | 12 (100%) | 12 (100%) |
| 40 | 12 (100%) | 12 (100%) |
| 50 | 12 (100%) | 12 (100%) |
| 65 | 11 (92%) | 11 (92%) |
| 75 | 10 (83%) | 10 (83%) |
| 85 | 9 (75%) | 9 (75%) |
Across all 147 studies, recruiting or not: 27% stop at 75 or younger and 22% at 65; 27% take children; 4% are for women only and 19% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Blood Coagulation Disorders studies take
Of 29 observational studies under Blood Coagulation Disorders, half reached primary completion within 33 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Observational | 33 mo20–59 · 29 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 147. Browse all 147 → or search them.
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)RecruitingNCT07059000Phase 38 countries
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingNCT06617897Phase 31 country
- External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform AnalysisRecruitingNCT074180991 country
- Investigation of the Genetics of Hematologic DiseasesRecruitingNCT027206791 country
- The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic TestingRecruitingNCT012808251 country
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitationNCT0576838612 countries
- Comparative Study of Tranexamic Acid Dosing in Cardiac SurgeryRecruitingNCT07164300Not applicable1 country
- Transfusion Surveillance in AnaesthesiaRecruitingNCT064031631 country
- Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)RecruitingNCT05776069Phase 1/28 countries
- Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet AgentRecruitingNCT05004233Not applicable1 country
- Early Genomic Testing for Inherited Bleeding DisordersRecruitingNCT06736158Early Phase 11 country
- Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)RecruitingNCT032559281 country
- Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on AnticoagulantsNot yet recruitingNCT065825631 country
- Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant TumorsRecruitingNCT059399601 country
- Biomarkers and Prediction of Tigecycline Induced Coagulation DysfunctionNot yet recruitingNCT05698160
- A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisWithdrawnNCT06963216Phase 3
- Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular SurgeryCompletedNCT05806346Not applicable1 country
- Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and SepsisCompletedNCT07892794Phase 21 country
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 37 countries
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/21 country
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 48 countries
- Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedNCT04684940Phase 1/27 countries
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 314 countries
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 14 countries
- The Effectiveness of a Novel Software Program to Help in ROTEM InterpretationCompletedNCT05591014Not applicable1 country
- Effects of Platelet Mimicking Nanoparticles in Patients With CirrhosisCompletedNCT060509931 country
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive, not recruitingNCT06224907Phase 31 country
- Analysis of the Coagulopathy Developed by COVID-19 Infected PatientsCompletedNCT043569501 country
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedNCT04323098Phase 34 countries
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT039017559 countries
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnNCT06291415Phase 15 countries
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedNCT03520712Phase 1/24 countries
- Gene Therapy Study in Severe Haemophilia A Patients (270-201)CompletedNCT02576795Phase 1/21 country
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedNCT03370913Phase 313 countries
- The Fear F8ctor Study - Does Fear Induce a Blood Curdling State?CompletedNCT02601053Not applicable
- An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 411 countries
- A Gene Transfer Study for Hemophilia ACompletedNCT03003533Phase 1/25 countries
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT030556111 country
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT029767539 countries
- Study of TU7710 in Warfarin Anti-coagulated Healthy Male SubjectsCompletedNCT06025552Phase 11 country
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT036553401 country
- The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated HeparinCompletedNCT06174961Phase 41 country
- Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BCompletedNCT032761303 countries
- Coagulation and Vitamin K in Head and Neck Microvascular Free Flap SurgeryCompletedNCT045174611 country
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsCompletedNCT03734588Phase 1/21 country
- A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment CentersTerminatedNCT053958581 country
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedNCT03392974Phase 31 country
- Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A ParticipantsCompletedNCT038763014 countries
- Study Using Plasma for Patients Requiring Emergency SurgeryWithdrawnNCT01221389Phase 41 country
- Palonosetron and Blood CoagulationStatus unknownNCT04507711Not applicable1 country